Overview
Emerging Therapies, Novel Mechanisms, and New Hope in the Treatment of PAH
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
The treatment landscape of pulmonary arterial hypertension (PAH) is poised to change dramatically in the near future. Designed with your questions in mind, this digital FAQ index offers succinct and relevant information for all practicing pulmonology and cardiology learners. What are some of the emerging therapies for PAH, and how do they differ from current treatment options? Which emerging therapies may be disease modifying? What clinical trial evidence is there for the treatments being investigated? What are the clinical implications of emerging therapies for the management of patients with PAH? Start the activity to find out the answers to these questions and more!
This activity is intended for pulmonologists, cardiologists, and the multidisciplinary team managing patients with suspected PAH.
Pulmonary arterial hypertension (PAH), or group 1 pulmonary hypertension, is a progressive disease with a 7-year survival rate of approximately 50% despite available treatments including phosphodiesterase-5 inhibitors (PDE5Is), prostacyclin analogs/receptor agonists, soluble guanylate cyclase stimulators (sGCs), and endothelin receptor antagonists (ERAs). These therapies target pathways underlying the pathophysiology of PAH that lead to impaired vasodilation, increased vasoconstriction, and proliferation in the pulmonary vasculature. However, as demonstrated by the mortality rate of PAH, it is evident that gaps in therapy remain; consequently, emerging treatment options targeting novel pathways are being developed. Moreover, it is hypothesized that a number of these investigational agents may exert disease-modifying effects, which could greatly improve patient outcomes. With the potential addition of a variety of emerging treatment options to the therapeutic armamentarium, clinicians require knowledge of the mechanisms, current clinical trial data, and clinical implications of these new agents to prepare for their incorporation within PAH management strategies.
Upon completion of this activity, learners will be able to:
• Assess unmet clinical needs in the treatment of PAH
• Contrast mechanisms of action of emerging therapies from standard of care
• Outline key points of clinical trial data for emerging therapies and their implications in addressing unmet patient needs
• Assess unmet clinical needs in the treatment of PAH
• Contrast mechanisms of action of emerging therapies from standard of care
• Outline key points of clinical trial data for emerging therapies and their implications in addressing unmet patient needs
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Merck & Co., Inc..
John Ryan, MD, MB, BCH, BAO
Professor of Medicine
Director of Pulmonary Hypertension Program
Director of Cardiology Fellowship
University of Utah
Salt Lake City, UT
Professor of Medicine
Director of Pulmonary Hypertension Program
Director of Cardiology Fellowship
University of Utah
Salt Lake City, UT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
John Ryan, MD, MB, BCH, BAO
Advisory Board: Bayer, Janssen PH
Consultant: Vertex
Speakers Bureau: Bayer, Janssen PH, United Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: sotatercept, imatinib, MK-5475, seralutinib, rodatristat ethyl, CS1, and KER-012 are investigational and are not approved for the treatment of PAH.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
